Q32 Bio Inc (QTTB) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket
 


Q32 Bio Inc   (NASDAQ: QTTB)


Q32 Bio Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Q32 Bio Inc 's ROA in the second quarter of 2026?
Q32 Bio Inc achieved a return on average assets (ROA) of 44.99 % in its second quarter of 2026, this is above QTTB's average return on assets of -26.29%.
Q32 Bio Inc assets over the 12 months ending in its second quarter of 2026 are valued at $75 million

ROA decreased relative to the period ending Mar 31 2026, due to the decline in net income.

However, within the Healthcare sector 23 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 69, from total ROA ranking in the first quarter of 2026 at 106.

What is ROA?



Return On Assets (Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 72.58 % -19.31 % -34.11 % -44.45 % -46.53 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million 34 33 30 -42 -52
Return On Assets (TTM) 44.99 % 52.78 % 44.62 % -56.2 % -60.4 %
QTTB's Total Ranking # 69 # 106 # 4095 # 4196 # 4268
Total Assets (TTM) in million 115 64 62 58 67
Seq. Total Assets Change 79.13 % 3.04 % 6.83 % -12.48 % -16.25 %
Seq. Net Income Change - - - - -



Return On Assets Company Ranking
Within: No.
Industry # 13
Sector # 24
Overall # 77

Return On Assets Statistics
High Average Low
53.33 %
-26.29 %
-61.16 %
(Mar 31 2026)   (Jun 30 2025)





Financial Statements
Q32 Bio Inc 's Assets $ 115 million QTTB's Balance sheet
Q32 Bio Inc 's Income $ -9 million Quarterly QTTB's Income Statement
QTTB's Income by Division See QTTB's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025
(Dec 31 2024)
FY 2024
(Dec 31 2023)
FY 2023
(Dec 31 2022)
FY 2022
(Dec 31 2021)
FY 2021
Y / Y Total Assets Change -32.86 % 9.95 % -62.93 % 7.73 % -19.67 %
Total Assets in million 62 93 85 228 212
Y / Y Net Income Change - - - - -
Net Income in million 30 -48 -113 -5 -96
Annual Return On Assets 47.77 % -51.34 % -133.58 % -2.19 % -45.23 %




Comment on QTTB's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 47.77 % compared to prior year, due to annual net income growth of % to $29.82 million, and due to decline of value in Q32 Bio Inc 's assets by -32.86 % to $62.42 million, compared to $62.42 a year before.


More Return On Assets Ratios
QTTB's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
QTTB's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for QTTB's Competitors
Subscribers only: Roa for Q32 Bio Inc 's Suppliers
Subscribers only: Return On Assets for QTTB's Customers

You may also want to know
QTTB's Roi QTTB's Inventory Turnover Ratio QTTB's Growth Rates QTTB's Dividend Comparisons
QTTB's Profitability Ratios QTTB's Asset Turnover Ratio QTTB's Dividend Growth
QTTB's Roe QTTB's Valuation Ratios QTTB's Financial Strength Ratios QTTB's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA
Elutia Inc   108.72 %
Silexion Therapeutics Corp  99.09 %
Arbutus Biopharma Corp  96.04 %
Pulmatrix Inc   94.81 %
Quince Therapeutics Inc   88.46 %
Interpace Biosciences Inc   85.91 %
Oncotelic Therapeutics Inc   81.75 %
Rigel Pharmaceuticals Inc  72.27 %
Actinium Pharmaceuticals Inc  71.73 %
Sanuwave Health Inc   71.60 %
Exelixis Inc   70.51 %
Rallybio Corporation  64.51 %
Oramed Pharmaceuticals Inc  64.18 %
Fortress Biotech Inc   60.88 %
Atlantic Coastal Acquisition Corp Ii  54.09 %
Lensar Inc   47.48 %
Elite Pharmaceuticals Inc   46.11 %
Omeros Corporation  46.05 %
Q32 Bio Inc   45.18 %
Aurinia Pharmaceuticals Inc   44.95 %
Agenus Inc  44.86 %
Earth Science Tech Inc   44.02 %
Liquidia Corporation  36.30 %
Ironwood Pharmaceuticals inc   34.34 %
Idexx Laboratories Inc  33.61 %
Tg Therapeutics Inc   33.59 %
Meiragtx Holdings Plc  29.37 %
Indivior Pharmaceuticals Inc   28.21 %
Qhslab Inc   27.12 %
Adma Biologics Inc   26.58 %


Date modified: 2026-09-10T17:14:56+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.